Terminated × Has results × Triple Negative Breast Neoplasms × Clear all Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
AMTEC IIT: Phase 2 Multiarm Study in TNBC
Phase 2 Terminated
24 enrolled 16 charts
INTEGRAL
Phase 2 Terminated
8 enrolled 10 charts
neoMono
Phase 2 Terminated
442 enrolled 42 charts
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase 1 Terminated
36 enrolled 7 charts
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
MK-2140-002
Phase 2 Terminated
102 enrolled 36 charts
ELEVATE TNBC
Phase 2 Terminated
92 enrolled 27 charts
TNBC
Phase 2 Terminated
115 enrolled 31 charts
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Phase 1/2 Terminated
10 enrolled 15 charts
AVID100 in Advanced Epithelial Carcinomas
Phase 1/2 Terminated
49 enrolled 19 charts
PERSEVERE
Phase 2 Terminated
52 enrolled 16 charts
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Phase 2 Terminated
30 enrolled 16 charts
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Phase 2 Terminated
315 enrolled 73 charts
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Phase 2 Terminated
6 enrolled 8 charts
Sitravatinib in Metastatic Breast Cancer
Phase 2 Terminated
3 enrolled 13 charts
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Phase 1/2 Terminated
9 enrolled 18 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Phase 1 Terminated
18 enrolled 9 charts
TENACITY
Phase 2 Terminated
18 enrolled 10 charts
TARA
Phase 2 Terminated
1 enrolled 11 charts
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Phase 1/2 Terminated
1 enrolled 6 charts
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 20 charts
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Phase 2 Terminated
8 enrolled 7 charts
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Phase 2 Terminated
11 enrolled 9 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1 Terminated
41 enrolled 24 charts
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Phase 2 Terminated
148 enrolled 9 charts
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Phase 1 Terminated
21 enrolled 19 charts
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
Phase NA Terminated
2 enrolled 5 charts
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Phase 1/2 Terminated
30 enrolled 14 charts
Neoadjuvant Immunotherapy in Brain Metastases
Phase 2 Terminated
1 enrolled 7 charts
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Phase 2 Terminated
5 enrolled 12 charts
0927GCC
Phase 2 Terminated
5 enrolled 7 charts
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Terminated
102 enrolled 51 charts
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
4 enrolled 10 charts
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase 1/2 Terminated
33 enrolled 14 charts
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
Phase 1 Terminated
1 enrolled 10 charts
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Phase 2 Terminated
29 enrolled 10 charts
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
23 enrolled 11 charts
A Study of LY3435151 in Participants With Solid Tumors
Phase 1 Terminated
2 enrolled 8 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
MK-8628-006
Phase 1 Terminated
13 enrolled 20 charts
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Phase 2 Terminated
32 enrolled 12 charts
BATON-BC
Phase 2 Terminated
30 enrolled 10 charts
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
13 enrolled 13 charts
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
Phase 1 Terminated
28 enrolled 25 charts
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
Phase 1 Terminated
1 enrolled 3 charts